Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Biphenotypic, Acute 7Burkitt Lymphoma 6Prostatic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 2Leukemia, Myeloid, Acute 2Down Syndrome 2Stomach Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Prostate Cancer Metastatic 1Pinealoma 1Pancreatitis 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Hodgkin Disease 1

Interventions

Cyclophosphamide 61Rituximab 50fludarabine 34Prednisone 33Doxorubicin 28Biopsy 26Vincristine 25Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 16Lenalidomide 16obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Hydrocortisone × 1 year × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡